International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists

+ Sample video: contact me for sample video

+ Information:

The “Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025” is a high-impact educational program taking place on October 27, 2025, both virtually and in person at the Congress-Centrum Koelnmesse in Cologne, Germany. Held in conjunction with the DGHO Annual Meeting, this program aims to bridge the knowledge gap between CAR T administering centers and the smaller community centers where the vast majority of oncology patients receive treatment. As multiple myeloma treatments have evolved dramatically, the workshop focuses on raising awareness of novel immune-based strategies in the relapsed refractory setting. It provides specific education on patient characteristics, treatment selection, and toxicity management for therapies such as antibody-drug conjugates, bispecific T-cell engagers, and CAR T cells, with a particular focus on B cell maturation antigen (BCMA) targets.

Learning Objectives

At the conclusion of this educational activity, you will be able to:

• Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.

• Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.

• Understand toxicities and their management post-novel immune strategies.

Target Audience

Are you a hematologist or oncologist treating patients with multiple myeloma?

If so, this workshop is for you!

This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Best for Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists.

Topics

• Advances in Diagnostics

  • Breakout Lesions/EMD

  • Single Cell Spatial Organization of Tumor Microenvironment

  • Advances in MRD Detection: Peripheral Blood and Bone Marrow Strategies

  • Monitoring for Infectious Post-T-Cell-Based Therapy

  • Predictors of Response and Mechanisms of Relapse

• Treatment with Novel Agents/Novel Combinations/Novel Concepts

  • CelMOD (Combinations)

  • 1 Line Therapy with Belamaf + Future Options

  • 2 Line Therapy with Belamaf/Occular Management

  • Bispecific Combinations/Trispecifics

  • CART Cells in Earlier Lines

• Management of Complications

  • CIDP Post-Cilta-cel

  • Immune Effector Cell Associated Secondary Malignancies

  • Bridging Therapies

  • Relapse Management

  • Modulation of the Target Antigen